UK markets close in 6 hours 40 minutes

BNTX Apr 2024 200.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
As of 01:22PM EDT. Market open.
Full screen
Previous close0.1500
Open0.0800
Bid0.0000
Ask2.1500
Strike200.00
Expiry date2024-04-19
Day's range0.0800 - 0.1500
Contract rangeN/A
Volume35
Open interest282
  • Barrons.com

    This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

    This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

  • Reuters

    UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

    BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.

  • Simply Wall St.

    BioNTech Full Year 2023 Earnings: Misses Expectations

    BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...